Daniel Goodman Net Worth

The estimated Net Worth of Daniel Wintner Goodman is at least $750 dollars as of 25 May 2021. Daniel Goodman owns over 5,000 units of Tonix Pharmaceuticals Corp stock worth over $750 and over the last 6 years he sold TNXP stock worth over $0. In addition, he makes $0 as Independent Director at Tonix Pharmaceuticals Corp.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Daniel Goodman TNXP stock SEC Form 4 insiders trading

Daniel has made over 1 trades of the Tonix Pharmaceuticals Corp stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of TNXP stock worth $5,600 on 25 May 2021.

The largest trade he's ever made was buying 5,000 units of Tonix Pharmaceuticals Corp stock on 25 May 2021 worth over $5,600. On average, Daniel trades about 1,250 units every 0 days since 2019. As of 25 May 2021 he still owns at least 5,001 units of Tonix Pharmaceuticals Corp stock.

You can see the complete history of Daniel Goodman stock trades at the bottom of the page.

Daniel Goodman biography

Dr. Daniel Wintner Goodman M.D. serves as Independent Director of the Company. He is President of The Midtown Practice for Psychiatry PC, a group practice of mental health professionals, which he co-founded in 2017, and Chief Executive Officer of Riverside Pharmaceuticals, a drug discovery company, which he founded in 2012. Dr. Goodman co-founded PsychoGenics Inc., a preclinical neuropharmacology company, in 1998, was its Chief Executive Officer from 1998 to 2000, and has served on its Board of Directors since 2000. Dr. Goodman graduated from Harvard Medical School and earned an M.B.A. from Columbia Business School.

How old is Daniel Goodman?

Daniel Goodman is 58, he's been the Independent Director of Tonix Pharmaceuticals Corp since 2019. There are 10 older and 5 younger executives at Tonix Pharmaceuticals Corp. The oldest executive at Tonix Pharmaceuticals Holding Corp is Adeoye Olukotun, 75, who is the Independent Director.

What's Daniel Goodman's mailing address?

Daniel's mailing address filed with the SEC is C/O TONIX PHARMACEUTICALS HOLDING CORP., 26 MAIN STREET, SUITE 101, CHATHAM, NJ, 07928.

Insiders trading at Tonix Pharmaceuticals Corp

Over the last 12 years, insiders at Tonix Pharmaceuticals Corp have traded over $155,884 worth of Tonix Pharmaceuticals Corp stock and bought 1,820,071 units worth $3,399,062 . The most active insiders traders include Ernest Mario, Seth Lederman et Bruce Daugherty. On average, Tonix Pharmaceuticals Corp executives and independent directors trade stock every 32 days with the average trade being worth of $2,734. The most recent stock trade was executed by Seth Lederman on 29 June 2022, trading 20,000 units of TNXP stock currently worth $34,200.

What does Tonix Pharmaceuticals Corp do?

tonix is developing innovative pharmaceutical products to address major public health challenges. in addition to tonmya for ptsd, tonix is developing tnx-601 (tianeptine oxalate), a clinical candidate at pre-ind (investigational new drug) application stage, designed as a daytime treatment for ptsd and tnx-801, a live synthetic version of horsepox virus, at the pre-ind application stage, to be developed as a potential smallpox-preventing vaccine. further information about tonix can be found at www.tonixpharma.com.

Complete history of Daniel Goodman stock trades at Tonix Pharmaceuticals Corp

Tonix Pharmaceuticals Corp executives and stock owners

Tonix Pharmaceuticals Corp executives and other stock owners filed with the SEC include:

• Seth Lederman,
  Chairman of the Board, President, Chief Executive Officer
• Dr. Seth Lederman M.D.,
  Co-Founder, Pres, CEO & Chairman
• Dr. Seth Lederman,
  Co-Founder, Pres, CEO & Chairman
• Dr. Gregory M. Sullivan M.D.,
  Chief Medical Officer & Sec.
• Gregory Sullivan,
  Secretary, Chief Medical Officer
• Bradley Saenger CPA, CPA,
  CFO & Treasurer
• Bradley Saenger,
  Chief Financial Officer, Treasurer
• Richard Bagger,
  Director
• Herbert Harris,
  Executive Vice President - Translational Medicine
• David Grange,
  Independent Director
• Margaret Bell,
  Independent Director
• James Treco,
  Lead Independent Director
• Adeoye Olukotun,
  Independent Director
• Daniel Goodman,
  Independent Director
• Jessica Morris,
  Chief Operating Officer
• Dr. Sina Bavari Ph.D.,
  Exec. VP of Infectious Disease R&D
• Dr. Anthony Macaluso Ph.D.,
  Exec. VP of Strategic Devel.
• Dr. Darryl Rideout Ph.D.,
  Exec. VP of Experimental Chemistry
• Siobhan Fogarty B.Sc., M.Sc.,
  Exec. VP of Product Devel.
• Dr. Bruce L. Daugherty M.B.A., Ph.D.,
  Exec. VP of Research
• Dr. Herbert W. Harris M.D., Ph.D.,
  Exec. VP of Translational Medicine
• Dr. R. Michael Gendreau,
  Consultant
• Dr. Daniel J. Clauw M.D.,
  Consultant
• Dr. Ronald R. Notvest,
  Exec. VP of Commercial Planning and Devel.
• Jessica Edgar Morris,
  Chief Operating Officer
• Charles E Iv Mather,
  Director
• Ernest Mario,
  Director
• John B Rhodes,
  Director
• Samuel R Saks,
  Director
• Patrick P Grace,
  Director
• Bruce Daugherty,
  See Remarks
• Stuart Davidson,
  Director
• Donald J Kellerman,
  See Remarks
• Leland Gershell,
  CFO and Treasurer
• Carolyn E. Taylor,
  Director
• Richard Newcomb Stillwell,
  Director